Our proprietary TCR-T cell therapy platform is supported by robust research, in collaboration with renowned laboratories, in the areas of autologous & allogeneic T cells and gene editing technologies.
January 18, 2021
|
Press Release
2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
December 9, 2020
2020
Lion TCR COO Dr Tina Wang’s sharing at Phar-East Asia's Pharma & Biotech Festival 2020
November 10, 2020
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
July 8, 2020
Lion TCR was featured in the Business Times “Fighting Covid-19 with local innovations”
April 6, 2020
Lion TCR joins the efforts to develop new strategies for protection and treatment of COVID-19
February 14, 2020
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
May 31, 2019
Events
2019
Prof. Antonio Bertoletti is named Top 0.1% Hepatitis B Expert in the World
May 27, 2019
Singapore DPM Heng Swee Keat and A*STAR Chairman Chan Lai Fung visit Lion TCR
March 31, 2019
Novel treatment for liver cancer gets funding boost
March 30, 2019
Local breakthrough research in liver cancer - Cell reprogramming can kill tumors
August 19, 2018
2018
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
May 27, 2018
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
January 24, 2018
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
August 28, 2017
2017
Singapore government support for global product commercialization of Lion TCR biotechnology company
August 16, 2017
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
